Live tape
Top 8, mentions 7d7,412NVDA1,293 mentions▲ +0.09GOOGL1,128 mentions▲ +0.04AVGO1,031 mentions▲ +0.05NKE1,013 mentions+0.02LULU956 mentions▲ +0.03TSLA894 mentions▲ +0.06META581 mentions▲ +0.05MSFT516 mentions▲ +0.06

Equity · Healthcare

IDYA

IDEAYA Biosciences, Inc. · NasdaqGS

$35.99 +0.28% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 26 sessions
$45 $25 10 Jun 17 Jul

The line runs $28 on 10 June through $35.99 on 17 July, on a scale from $25 to $45. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of IDYA over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $28 on 10 June 2026 through $35.99 on 17 July 2026.

Market cap $3.5B
52-week range $21.42 – $41
Avg volume 281.4K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

IDYA insider trades

SEC Form 4 · last 90 days · newest reported trade 7 Jul 2026
Open-market buys 0
Open-market sells 1
Net sold $382K
Non-trade filings 1
Date Insider Type Shares Value
07 Jul 2026 Ruiz Briseno Andres Chief Accounting Officer Sell 9,550 $382K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
07 Jul 2026 Ruiz Briseno Andres Chief Accounting Officer Option exercise 9,550 $123K

IDYA reported financials

SEC EDGAR XBRL

IDYA reported revenue of $218.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$113.7M.

Figure Reported Period
Revenue $218.7M 31 Dec 2025 fiscal year
Net income −$113.7M 31 Dec 2025 fiscal year
Diluted EPS −$1.28 31 Dec 2025 fiscal year
Total assets $1.3B 30 Jun 2026 at period end
Total equity $1.2B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

IDYA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.22 $9M
31 Mar 2026 Q1 2026 $-1.11 $7M
31 Dec 2025 FY 2025 $-1.28 $219M
30 Sep 2025 Q3 2025 $1.33 $208M
30 Jun 2025 Q2 2025 $-0.88 —
31 Mar 2025 Q1 2025 $-0.82 —
31 Dec 2024 FY 2024 $-3.36 $7M
30 Sep 2024 Q3 2024 $-0.60 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

IDYA institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a IDYA position for the quarter ended 30 Jun 2026 — a combined $256.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Added +26.9% shares 5,010,030 $186.7M
Fisher Asset Management Held (±25%) −3.6% shares 851,306 $31.7M
Citadel Advisors Trimmed −55.8% shares 300,438 $11.2M
Balyasny Asset Management Added +42.8% shares 297,565 $11.1M
Man Group Added +42.9% shares 245,492 $9.1M
AQR Capital Management Added +61.2% shares 67,976 $2.5M
Tudor Investment Corp Held (±25%) +6.0% shares 45,287 $1.7M
Two Sigma Investments Trimmed −65.4% shares 41,205 $1.5M
D. E. Shaw & Co. New position 20,763 $774K
Millennium Management Trimmed −95.4% shares 10,500 $391K

Source: SEC EDGAR 13F filings

IDYA fails-to-deliver

SEC CNS data

On 14 Aug 2026, 3 shares of IDYA failed to deliver (about $110) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
14 Aug 2026 3 $110 <0.001%
13 Aug 2026 3 $111 <0.001%
11 Aug 2026 1,136 $42K 0.001%
30 Jul 2026 6 $214 <0.001%

Source: SEC fails-to-deliver (CNS) data